These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 31753017)

  • 1. Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples.
    Scott EM; Jacobus EJ; Lyons B; Frost S; Freedman JD; Dyer A; Khalique H; Taverner WK; Carr A; Champion BR; Fisher KD; Seymour LW; Duffy MR
    J Immunother Cancer; 2019 Nov; 7(1):320. PubMed ID: 31753017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncolytic herpesvirus expressing PD-L1 BiTE for cancer therapy: exploiting tumor immune suppression as an opportunity for targeted immunotherapy.
    Khalique H; Baugh R; Dyer A; Scott EM; Frost S; Larkin S; Lei-Rossmann J; Seymour LW
    J Immunother Cancer; 2021 Mar; 9(4):. PubMed ID: 33820820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Revolutionizing cancer treatment: the power of bi- and tri-specific T-cell engagers in oncolytic virotherapy.
    Zarezadeh Mehrabadi A; Tat M; Ghorbani Alvanegh A; Roozbahani F; Esmaeili Gouvarchin Ghaleh H
    Front Immunol; 2024; 15():1343378. PubMed ID: 38464532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies.
    Freedman JD; Hagel J; Scott EM; Psallidas I; Gupta A; Spiers L; Miller P; Kanellakis N; Ashfield R; Fisher KD; Duffy MR; Seymour LW
    EMBO Mol Med; 2017 Aug; 9(8):1067-1087. PubMed ID: 28634161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic adenovirus with MUC16-BiTE shows enhanced antitumor immune response by reversing the tumor microenvironment in PDX model of ovarian cancer.
    Wang Q; Ma X; Wu H; Zhao C; Chen J; Li R; Yan S; Li Y; Zhang Q; Song K; Yuan C; Kong B
    Oncoimmunology; 2022; 11(1):2096362. PubMed ID: 35800156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells.
    Freedman JD; Duffy MR; Lei-Rossmann J; Muntzer A; Scott EM; Hagel J; Campo L; Bryant RJ; Verrill C; Lambert A; Miller P; Champion BR; Seymour LW; Fisher KD
    Cancer Res; 2018 Dec; 78(24):6852-6865. PubMed ID: 30449733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic adenovirus and gene therapy with EphA2-BiTE for the treatment of pediatric high-grade gliomas.
    Arnone CM; Polito VA; Mastronuzzi A; Carai A; Diomedi FC; Antonucci L; Petrilli LL; Vinci M; Ferrari F; Salviato E; Scarsella M; De Stefanis C; Weber G; Quintarelli C; De Angelis B; Brenner MK; Gottschalk S; Hoyos V; Locatelli F; Caruana I; Del Bufalo F
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager.
    de Sostoa J; Fajardo CA; Moreno R; Ramos MD; Farrera-Sal M; Alemany R
    J Immunother Cancer; 2019 Jan; 7(1):19. PubMed ID: 30683154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic Adenoviral Delivery of an EGFR-Targeting T-cell Engager Improves Antitumor Efficacy.
    Fajardo CA; Guedan S; Rojas LA; Moreno R; Arias-Badia M; de Sostoa J; June CH; Alemany R
    Cancer Res; 2017 Apr; 77(8):2052-2063. PubMed ID: 28143835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Multifaceted Role of Macrophages in Oncolytic Virotherapy.
    Hofman L; Lawler SE; Lamfers MLM
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted BiTE Expression by an Oncolytic Vector Augments Therapeutic Efficacy Against Solid Tumors.
    Speck T; Heidbuechel JPW; Veinalde R; Jaeger D; von Kalle C; Ball CR; Ungerechts G; Engeland CE
    Clin Cancer Res; 2018 May; 24(9):2128-2137. PubMed ID: 29437789
    [No Abstract]   [Full Text] [Related]  

  • 13. T-cell subsets in peripheral blood and tumors of patients treated with oncolytic adenoviruses.
    Taipale K; Liikanen I; Juhila J; Karioja-Kallio A; Oksanen M; Turkki R; Linder N; Lundin J; Ristimäki A; Kanerva A; Koski A; Joensuu T; Vähä-Koskela M; Hemminki A
    Mol Ther; 2015 May; 23(5):964-973. PubMed ID: 25655312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cell engager-armed oncolytic vaccinia virus significantly enhances antitumor therapy.
    Yu F; Wang X; Guo ZS; Bartlett DL; Gottschalk SM; Song XT
    Mol Ther; 2014 Jan; 22(1):102-11. PubMed ID: 24135899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses.
    Scott EM; Duffy MR; Freedman JD; Fisher KD; Seymour LW
    Macromol Biosci; 2018 Jan; 18(1):. PubMed ID: 28902983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural states.
    Pellizzari G; Hoskin C; Crescioli S; Mele S; Gotovina J; Chiaruttini G; Bianchini R; Ilieva K; Bax HJ; Papa S; Lacy KE; Jensen-Jarolim E; Tsoka S; Josephs DH; Spicer JF; Karagiannis SN
    EBioMedicine; 2019 May; 43():67-81. PubMed ID: 30956175
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Giehl E; Kosaka H; Liu Z; Feist M; Kammula US; Lotze MT; Ma C; Guo ZS; Bartlett DL
    Front Immunol; 2021; 12():610042. PubMed ID: 33679747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arming oncolytic viruses with bispecific T cell engagers: The evolution and current status.
    Wang Y; Cheng P
    Biochim Biophys Acta Mol Basis Dis; 2024 Feb; 1870(2):166962. PubMed ID: 37984801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses.
    Crupi MJF; Bell JC; Singaravelu R
    Stem Cells; 2019 Jun; 37(6):716-723. PubMed ID: 30875126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of actin dynamics as potential macrophage subtype-targeting anti-tumour strategy.
    Pergola C; Schubert K; Pace S; Ziereisen J; Nikels F; Scherer O; Hüttel S; Zahler S; Vollmar AM; Weinigel C; Rummler S; Müller R; Raasch M; Mosig A; Koeberle A; Werz O
    Sci Rep; 2017 Jan; 7():41434. PubMed ID: 28134280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.